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Abstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. 
However, most patients will eventually become refractory to these agents. Ixabepilone is a 
newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although 
it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients 
that are refractory to taxanes. This review summarizes the pharmacology of ixapebilone and 
clinical trials with the drug both as a single agent and in combination. Data were obtained using 
searches of PubMed and abstracts of the annual meetings of the American Society of Clinical 
Oncology and the San Antonio Breast Cancer Symposium from 1995 to 2008. Ixapebilone is 
a semi-synthetic analog of epothilone B that acts to induce apoptosis of cancer cells via the 
stabilization of microtubules. Phase I clinical trials have employed various dosing schedules 
ranging from daily to weekly to 3-weekly. Dose-limiting toxicites included neuropathy and 
neutropenia. Responses were seen in a variety of tumor types. Phase II studies verifi ed activity 
in taxane-refractory metastatic breast cancer. The FDA has approved ixabepilone for use as 
monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer. 
Ixabepilone is an effi cacious option for patients with refractory metastatic breast cancer. The 
safety profi le is similar to that of taxanes, with neuropathy and neutropenia being dose-limiting. 
Studies are ongoing with the use of both iv and oral formulations and in combination with other 
chemotherapeutic and biologic agents.
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Introduction
Although great strides have been made in the treatment of breast cancer, once meta-
static, cure is unlikely. There are many agents available to treat metastatic breast cancer 
(MBC), and decisions on treatment must take into account the balance between effi cacy 
and tolerability. Although, there are many new biological agents in clinical trials, 
chemotherapy is still an important backbone of the treatment. The recent approval of 
new agents has added to the repertoire available for the treatment of MBC (Gradishar 
et al 2005; Perez et al 2007; Thomas et al 2007).
The taxanes are the mainstays of chemotherapy for MBC. However, because all 
patients will eventually become refractory to these, new strategies are needed for 
taxane-refractory MBC. One drug that has shown effi cacy both preclinically and clini-
cally in patients resistant to docetaxel or paclitaxel is ixabepilone (BMS-247550). This 
drug fi lls an important void in chemotherapeutic options for patients.
Pharmacology of ixapebilone
Ixapebilone is in the epothilone class of chemotherapeutic drugs. Epothilones were 
initially discovered when fungicidal activity was observed by the myxobacterium 
Sorangium cellolosum and later these agents were found to interact with and sta-
bilize microtubules (Bollag et al 1995; Gerth et al 1996). Microtubules help form 
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the cytoskeleton and have vital roles in various cellular 
processes including cell signaling and mitosis. Microtubules 
are made up of 2 subunits, α and β. Microtubules have been 
an attractive target for many chemotherapeutic drugs, which 
exert their cytotoxic effects via microtubule stabilization or 
destabilization (Jordan et al 2004). Ixapebilone is a semi-
synthetic analog of epothilone B, created by the substitution 
of an azide group for oxygen in the macrolide ring (Fumoleau 
et al 2007) (Figure 1). Similar to taxanes, epothilones exert 
their effect by binding to and subsequently polymerizing 
and stabilizing microtubules, thus preventing mitosis and 
resulting in apoptosis (Bollag et al 1995). Epothilones spe-
cifi cally bind to β-tubulin, although the exact binding site is 
not known (Giannakakou et al 2000). Despite the fact that 
epothilones bind close to or at the paclitaxel binding site on 
tubulin (Nogales et al 1995; Ojima et al 1999; Giannakakou 
et al 2000), there are also data from yeast studies to suggest 
that the binding of epothilones to tubulin and the subsequent 
microtubule formation may be distinct from that of pacli-
taxel (Bode et al 2002). Another important difference is that 
epothilones have been shown to have activity both preclini-
cally and clinically in taxane resistance, likely due to the 
fact that the epothilones are not substrates for P-glycoprotein 
or MRP-1 and are active in β-tubulin mutations (He et al 
2001a; Lee et al 2006). MDR-1 drug transporter expressing 
tumors are also sensitive to epothilones (McDaid et al 2002). 
In breast cancer cell lines and xenograft models, including 
those with multidrug resistance, ixapebilone has been shown 
to have cytotoxicity values ranging from 1.4 to 45 nM and 
has improved cytotoxicity over paclitaxel (Lee et al 2001, 
2006). Both an iv and oral formulation of ixabepilone have 
undergone clinical studies, although it is the iv form that has 
been approved for the treatment of breast cancer. Further 
trials with the oral formulation are awaited.
Cell lines resistant to epothilones have been reported 
(Giannakakou et al 2000; He et al 2001b). The resistance 
is felt to be secondary to point mutations in the β-tubulin 
subunit, rather than MDR1 expression. These cells lines of 
various tumor types including ovarian and nonsmall-cell lung 
cancers have been to shown to exhibit resistance to other 
taxanes as well. It has been shown that these point mutations 
lead to less endogenous microtubule stabilization (He et al 
2001a). These cell lines resistant to epothilones have also 
been found to have slower growth, which could be second-
ary to the endogenously more stable microtubules or could 
be due to an additional mechanism.
Pharmacokinetic studies with ixabepilone given on 
a daily dosing schedule have demonstrated a rapid 1-log 
decline after drug infusion, later followed by a prolonged 
elimination phase, not unlike taxanes (Abraham et al 2003). 
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Figure 1 Chemical structures of the epothilones under clinical development. (A) Structure of epothilone B, ixabepilone, and BMS-310705. (B) Structure of epothilone D. (C) 
Structure of epothilone D second generation. From Fumoleau P, Coudert B, Isambert N, et al. 2007. Novel tubulin-targeting agents: anticancer activity and pharmacologic profi le 
of epothilones and related analogues. Ann Oncol, 18(Suppl 5):v9–15, by permission of Oxford University Press © 2007.
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The mean half-life of the drug was 16.8 hours. Clearance 
was rapid, dose-independent, and not associated with body 
weight or surface area. Dosing every 21 days showed a 
similar plasma concentration curve and independence of 
clearance, elimination, and dose (Mani et al 2004; Gadgeel 
et al 2005). The mean half-life was 38.5 hours at a dose of 
40 mg/m² given every 21 days (Mani et al 2004).
Pharmacodynamic studies with daily dosing did not 
show any correlation between area under the curve (AUC) 
and neutropenia (Abraham et al 2003). Similarly, there was 
no correlation with AUC and neutropenia in the 21-day 
dosing schedule (Mani et al 2004). However, the percent-
age change in absolute neutrophil count was signifi cantly 
negatively correlated with increasing doses of ixabepilone 
(Gadgeel et al 2005). Pharmacodynamic studies exploring 
microtubule bundle formation and the subsequent effects on 
plasma ixabepilone concentration and extent of neutropenia 
have been performed (McDaid et al 2002; Mani et al 2007). 
Microctubule bundle formation is a surrogate for ixabepilone 
binding to β-tubulin and drug binding increases with greater 
ixabepilone concentration. This binding is correlated with 
AUC. Interestingly, it has been shown that there were more 
tumor cells with microtubule bundle formation than periph-
eral blood mononuclear cells after ixabepilone dosing (Mani 
et al 2007). The degree of neutropenia has been found to be 
correlated with the extent of microtubule bundle formation 
in peripheral blood mononuclear cells.
Clinical trials with ixabepilone
Phase I studies (Table 1)
Numerous phase I trials have evaluated the optimum dose and 
toxicity with ixabepilone. There have been numerous dosing 
schedules in both oral and iv formulations used in these trials. 
The earliest phase I trial was reported by Awada et al (2001) 
and employed a weekly iv dosing schedule. There were 
various tumor types in this study including breast cancer. 
At the time when preliminary results were presented, the 
current dose level was 30 mg/m²/week. Responses included 
stable disease in patients who were previously treated with a 
taxane with toxicities including fatigue, anorexia, arthralgia/
myalgia, neuropathy, and myelosuppression. Another phase 
I study using weekly dosing has been presented (Burris et al 
2002). In this study the maximum tolerated dose (MTD) 
was 25 mg/m²/week. Although there was minimal neutro-
penia, grade 3 toxicities included fatigue, nausea, diarrhea, 
myalgia/arthralgia, and neuropathy. This study initially used 
a 30-minute infusion, but was later amended to allow for a 
1-hour infusion time, as well as a 3 weeks on, 1 week off 
dosing schedule in attempts to reduce neuropathy. Responses 
were seen in patients who had previously received taxane 
therapy. Hao et al (2002) explored continuous weekly dosing 
in another phase I trial. In this study, dose-limiting toxicities 
were grade 3 fatigue and grade 4 neutropenia at the 20 mg/m² 
and 30 mg/m² dose levels. Neuropathy was more frequent 
in patients who were heavily pretreated. Decreases in tumor 
markers were seen in taxane-refractory patients.
The use of 3-weekly dosing was also evaluated in the 
phase I setting. The earliest report was the preliminary 
data of Spriggs et al (2001). In this trial, a 1-hour infusion 
of ixabepilone was given to patients in dose levels rang-
ing from 7.4 mg/m² to 65 mg/m². MTD was determined 
to be 50 mg/m². Dose-limiting toxicities included grade 
3 arthralgias and myalgias, grade 3 neuropathy, grade 4 
neutropenia, febrile neutropenia, pneumococcal sepsis, 
and 1 death. Antitumor activity was seen again in taxane 
pretreated patients and a complete response was seen in a 
patient with ovarian cancer. Another phase I study using a 
1-hour infusion every 3 weeks also determined the MTD 
to be 50 mg/m² (Aghajanian et al 2007). In this study, the 
most common toxicities limiting dose were neutropenia, 
stomatitis, myalgia, and arthralgia. A 3-hour infusion time 
was also investigated in this trial and no dose-limiting 
toxicities (DLTs) were seen at doses less than 50 mg/m² 
when the drug was administered over 3 hours. Eight patients 
attained an objective response, many of whom had previ-
ously received taxane therapy. Mani et al (2004) performed 
a phase I study using 3-weekly dosing with 1-hour infusion 
times. The recommended phase II dose of ixabepilone was 
determined to be 40 mg/m². Similarly to previous trials, 
the dose-limiting toxicities included grade 4 and febrile 
neutropenia; however, grade 3 abdominal pain, nausea, and 
vomiting were also seen. A Japanese phase I trial using a 
3-hour infusion every 3 weeks also determined the tolerable 
dose of ixabepilone to be 40 mg/m² (Shimizu et al 2008); 
DLT was grade 4 neutropenia. There were no objective 
responses, but over two-thirds of patients had stable disease. 
Linear pharmacokinetics were observed.
A dose of 40 mg/m² dose was again verifi ed as the MTD 
in a phase I study in patients with refractory, advanced solid 
tumors and the DLT was neutropenia (Gadgeel et al 2005). 
Grade 1 and 2 neuropathy was observed in 3 out of 5 patients 
who received greater than 28.6 mg/m² for at least 2 cycles. 
Fatigue was also commonly seen. No patients met criteria 
for partial responses; however, there were minor responses 
and stable disease was seen. Pharmacokinetics were linear 
and there was evidence to suggest that there was a correlation 
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Table 1 Summary of phase I studies
Study Dose/dosing schedule Maximum tolerated 
dose
Dose-limiting or grade 3/4 
toxicities
Activity
Awada et al 2001 Weekly Not yet determined; 
Enrolling at 30 mg/m²/
week
Grade 3 sensory neuropathy Stable disease seen in multiple 
tumor types
Burris et al 2002 Weekly 25 mg/m²/week Cumulative sensory neu-
ropathy; Grades 3/4 fatigue, 
nausea, diarrhea, myalgia/
arthralgia
Partial and minor responses 
seen in multiple tumor types
Hao et al 2002 Weekly Enrolling at 20 
mg/m²/week in heavily 
pretreated patients 
and 30 mg/m²/week in 
minimally pretreated 
patients
Grade 3 fatigue, Grade 4 
neutropenia
Minor response in melanoma 
patient, tumor marker decline 
in taxane-refractory ovarian 
and prostate cancer patients
Spriggs et al 2001 Q 3 weeks; 1-hour infusion 50 mg/m² Grade 3 neuropathy, Grade 4 
neutropenia with sepsis and 
death, Grade 3 myalgia/
arthralgia
Complete response in patient 
with paclitaxel-refractory 
ovarian cancer, also partial 
responses and stable disease 
seen in multiple tumor types
Mani et al 2004 Q 3 weeks; 1-hour infusion 50 mg/m²; recom-
mended phase II dose 
40 mg/m²
Sepsis and death, Grade 
4 neutropenia, Grade 3 
abdominal pain/nausea/vom-
iting, Grade 3 neoropathy
4 patients with objective 
partial and minor responses, 
responses include taxane-
refractory disease
Gadgeel et al 2005 Q 3 weeks; 1-hour infusion 40 mg/m² Grade 4 neutropenia, 
neutropenic sepsis, grade 
3 nausea/emesis, grade 4 
myalgias, grade 3 fatigue, 
grade 4 diarrhea, grade 3 and 
4 thrombocytopenia
Tumor shrinkage not meeting 
criteria for partial response, 
stable disease in multiple 
tumor types
Shimizu et al 2008 Q 3 weeks; 3-hour infusion 40 mg/m² Grade 4 neutropenia, grade 
3 nausea, vomiting, and 
dehydration
Stable disease
Aghajanian et al 2007 Q 3 weeks; 1-hour and 3-hour 
infusion
50 mg/m² Neutropenic infection and 
death, death from pneumonia 
and sepsis, grade 3 sen-
sory neuropathy, grade 3/4 
nausea/vomiting, grade 3/4 
fatigue, grade 3/4 myalgia/
arthralgia
Complete and partial 
responses in multiple tumor 
types and taxane-pretreated 
patients
Thambi et al 2003 Daily for 3 days every 21 days Recommended phase 
II dose: 8 mg/m²/day x 
3 days
Grade 3 leukopenia, grade 4 
neutropenia, grade 3 throm-
bocytopenia, grade 3 nausea, 
grade 3/4 vomiting, grade 3 
anorexia
Stable disease, nonconfi rmed 
tumor shrinkage
Abraham et al 2003 Daily for 5 days every 21 days Recommended phase 
II dose: 6 mg/m²/day x 
5 days
Grade 4 neutropenia, grade 
3 fatigue, grade 3 mucositis, 
grade 3 anorexia
Partial responses including 
taxane-refractory patients, 
reduction in CA-125 in ovar-
ian cancer patients
Zhuang et al 2005 Daily for 3 days every 21 days Recommended phase 
II dose: 8-10 mg/m²/
day x 3 days
Grade 4 neutropenia, grade 
3 fatigue, grade 3 hyponatre-
mia, grade 3 anorexia, grade 
3 ileus, grade 3 stomatitis, 
grade 3 emesis
Prolonged stable disease in 
multiple tumor types
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between the change in neutrophil count and the time at which 
the ixabepilone plasma concentration was 15 ng/mL.
In attempts to augment the degree of neurotoxicity 
observed with 3-weekly dosing, daily administration of 
ixabepilone was evaluated in the phase I setting. Less neu-
ropathy has been observed in daily compared with 3-weekly 
dosing. Abraham et al (2003) examined a dosing schedule of 
treatment daily for 5 consecutive days, with 21-day dosing 
intervals (Abraham et al 2003). Ixabepilone was given as 
a 1-hour infusion. Most patients had received prior taxane 
therapy and half had received 6 prior lines of treatment. 
MTD was 6 mg/m². Higher doses (8 mg/m²) were compli-
cated with neutropenia despite fi lgrastim support. Neuro-
toxicity was generally mild and no grade 3 or 4 neuropathy 
was observed. Five out of 27 patients enrolled achieved a 
partial response, and these patients had received prior taxane 
therapy. Preliminary data presented explored a daily dosing 
schedule given every 3 days where the recommended phase 
II dose was 8 mg/m² for 3 days, with cycles every 21 days 
(Thambi et al 2003). A published report of a daily dosing 
schedule for 3 days also determined the MTD to be at a dose 
of 8 mg/m²/day. This was given as a 1-hour infusion and 
similarly to the Abraham study, the DLT was neutropenia and 
there were no cases of dose-limiting neurotoxicity (Zhuang 
et al 2005). Seventeen of the 26 enrolled patients had received 
prior taxane therapy and the median number of prior therapies 
received was 4. Although no responses were observed in 
this trial, patients with renal cell carcinoma, ovarian cancer, 
and primary peritoneal mesothelioma had prolonged stable 
disease up to 28 months.
Numerous phase I studies have also evaluated the tox-
icities associated with ixabepilone given in combination 
with other chemotherapeutic and biologic agents (Plum-
mer et al 2002; Anderson et al 2004; Bunnell et al 2006; 
Hensley et al 2007). Preliminary results of a study explor-
ing the use of ixabepilone in combination with carboplatin 
revealed partial responses in patients with breast cancer as 
well as neuroendocrine cancer (Plummer et al 2002). Some 
patients also achieved stable disease. Patients were relatively 
chemotherapy-naïve as only up to 2 prior therapies were 
allowed. DLT was reached at 40 mg/m² of ixabepilone and 
an AUC of 5 for carboplatin. A phase I/II study conducted in 
patients with MBC evaluated the combination of ixabepilone 
with capecitabine (Bunnell et al 2006). Eligible patients had 
received prior taxane and anthracycline-based treatment in 
the adjuvant or metastatic but could not have received greater 
than 3 prior regimens for metastatic disease. Two treatment 
schedules were evaluated; a single 3-hour infusion or daily 
therapy given over 1 hour for 3 days every 21 days. The 
recommend phase II dose for ixabepilone was determined 
to be 40 mg/m² as a single infusion and for capecitabine 
was 2000 mg/m² given on days 1–14 every 3 weeks. Nearly 
half of the patients had 2 or more therapies in the metastatic 
setting. Fifteen of 50 enrolled patients achieved a complete 
(1 patient) or partial response (14 patients) yielding an overall 
response rate of 30%. Responses had a median duration of 
nearly 7 months.
Phase II studies in breast cancer (Table 2)
Based on ample evidence of response and safety in early tri-
als, various phase II studies were designed for patients with 
varying levels of previous therapies. Three published phase 
II trials used a daily dosing schedule. Low et al (2005) used 
a 6 mg/m²/day dosing schedule on days 1–5 every 3 weeks 
in patients with taxane-refractory breast cancer. A total of 
37 patients were enrolled and 43% had received between 
3 and 9 prior chemotherapy regimens in the metastatic 
setting. The objective response rate (ORR) was 22% and 
patients received a median of 4 cycles (range 1–11 cycles) 
with a median time to progression of 80 days for all sub-
jects. An additional 35% of patients had stable disease for 
at least 6 weeks. Toxicities were generally mild. Twelve 
patients required dose reductions secondary to toxicities 
including neuropathy, diarrhea, fatigue, neutropenia, and 
myalgia. Only 1 patient developed grade 3 neuropathy, 
although mild neuropathy (grades 1 or 2) was frequent (83% 
of total subjects).
Another phase II study examined a daily dosing sched-
ule for 5 consecutive days at a dose of 6 mg/m²/day given 
every 21 days (Denduluri et al 2007a). Patients in this trial 
were taxane-naïve; however, any number of non-taxane 
prior therapies was allowed. Of the 23 patients enrolled, 
70% had prior chemotherapy, which was primarily adjuvant 
anthracycline. ORR was 57%. Stable disease for at least 6 
weeks was achieved in 26%. Median time to progression 
was 5.5 months, and for partial responders, the median dura-
tion of response was 5.6 months. Four patients had toxicity 
necessitating removal from study (grade 3 weight loss, grade 
3 motor neuropathy, prolonged autonomic neuropathy, and 
grade 2 fatigue) and dose reductions occurred in 4 patients 
(prolonged neutropenia, neuropathy, and fatigue). Severe 
neuropathy was infrequent with 13% having grade 2 sensory 
neuropathy, 4% grade 2 motor neuropathy, no patients with 
grade 3 sensory neuropathy, and 1 patient with grade 3 motor 
neuropathy. The same group performed a small study using 
daily dosing but with 3 consecutive days of therapy at initial 
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doses of 8 mg/m²/day which was titrated up to 10 mg/m²/day 
if tolerated (Denduluri et al 2007b). Of the 12 patients 
enrolled, all had received previous taxanes. Median number 
of previous therapies in the metastatic setting was 3.5. The 
treatment had an acceptable safety profi le; however, no 
complete or partial responses were seen and the study was 
stopped. Possible explanations for the lack of response may 
be decreased dose intensity in comparison with other studies 
with daily dosing.
There have also been numerous phase II studies with 
3-weekly dosing in patients with MBC, in both taxane-naïve 
and taxane-refractory patients. Perez et al (2007) examined 
the effi cacy of ixabepilone in a heavily pretreated patient 
population which had received prior anthracycline, taxane, 
and capecitabine therapies. Dose was 40 mg/m² given as a 
3-hour infusion every 3 weeks. This was the third line of 
treatment in the metastatic setting for 88% of the 126 patients 
enrolled. An independent radiology facility assessed ORR at 
Table 2 Summary of phase II studies in metastatic breast cancer
Study Number of 
patients
Dosing schedule Objective response 
rate
Survival endpoints Selected grade 3/4 
toxicities (%)
Low et al 2005; 
Prior taxane
37 6 mg/m²/day on days 
1–5 every 3 weeks
22% (95% CI, 9.8%–
38.2%)
Median time to 
progression 80 days
Neutropenia (35%)
Febrile neutropenia 
(14%)
Thrombocytopenia (8%)
Fatigue (13%)
Sensory neuropathy (3%)
Myalgia/arthralgia (3%)
Nausea (5%)
Constipation (11%)
Diarrhea (5%)
Denduluri et al 
2006; Prior 
taxane
12 8 mg/m²/day on 
days 1–3 every 3 
weeks (increased to 
10 mg/m²/day if no 
toxicity)
No objective responses; 
10 patients with stable 
disease for 6 weeks
Median time 
to progression 
2.7 months
Neutropenia (17%)
Thrombocytopenia (8%)
Allergic reaction (8%)
Denduluri et al 
2007; No prior 
taxane
23 6 mg/m²/day on days 
1–5 every 3 weeks
57% (95% CI 
34.5%–76.8%)
Median time 
to progression 
5.5 months
Neutropenia (22%)
Thrombocytopenia (4%)
Arthralgia/myalgia (4%)
Diarrhea (4%)
Fatigue (13%)
Motor neuropathy (4%)
Nausea (9%)
Perez et al 
2007; Prior 
taxane
126 40 mg/m² every 
21 days
Independent radiology 
facility 11.5% (95% CI 
6.3%–18.9%)
Investigator assessed 
18.3% (95% CI 
11.9%–26.1%)
Median progression-
free survival 
3.1 months; median 
overall survival 
8.6 months
Neutropenia (54%)
Febrile neutropenia (3%)
Thrombocytopenia (8%)
Sensory neuropathy 
(14%)
Fatigue/asthenia (14%)
Myalgia/arthralgia (8%)
Nausea (2%)
Thomas et al 
2007; Prior 
taxane
49 40 mg/m² every 
3 weeks
12% (95% CI 
4.7%–26.5%)
Median time to pro-
gression 2.2 months, 
median survival 
7.9 months
Febrile neutropenia (6%)
Sensory neuropathy (12%
Fatigue (27%
Nausea/vomiting (26%)
Myalgia/arthralgia (12%)
Roche et al 
2007; Prior 
adjuvant tax-
ane allowed if 
1 year since 
treatment
93 40 mg/m² every 
3 weeks
41.5% (95% CI 
29.4%–54.4%)
Median time to pro-
gression 9.3 months, 
median survival 
29.9 months
Neutropenia (58%)
Febrile neutropenia (6%)
Seonsory neuropathy 
(20%)
Motor neuropathy (5%)
Myalgia/arthralgia (13%)
Nausea/vomiting (7%)
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11.5% and the investigator-assessed ORR was 18.3%. Stable 
disease was achieved in 50% of patients. The median overall 
survival was 8.6 months. The adverse effects encountered 
were generally managable. Grade 3 and 4 neutropenia was 
seen in about half the patients, but febrile neutropenia was 
uncommon. The most frequent nonhematologic toxicity 
was peripheral sensory neuropathy which was seen in 60%, 
but this generally reversed after 5 weeks.
Another study using the same dose and schedule of ixa-
bepilone was evaluated in taxane refractory patients (Thomas 
et al 2007). Of the 66 patients, 86% had received 2 prior 
therapies and 98% of those patients had either docetaxel or 
paclitaxel as their most recent treatment in the metastatic 
setting. ORR was 12%, similar to that in the Perez study, 
and stable disease was achieved in 41% of patients. Fifty-fi ve 
percent of patients developed grade 1 or 2 toxicity. Serious 
adverse effects were seen in 22% of patients. This trial was 
initially designed to give 50 mg/m² of ixabepilone over 1 
hour, and 38% of patients at that dose developed grade 3 
sensory neuropathy. When the dose was lowered to 40 mg/m² 
and extended over a 3-hour infusion time, the incidence of 
severe neuropathy dropped to 12%.
Ixabepilone has also been studied in the first-line 
metastatic setting (Roche et al 2007), with a 40 mg/m² dose 
given as a 3-hour infusion every 3 weeks. All 65 patients had 
received anthracycline-based therapy in the adjuvant setting. 
The primary endpoint was objective response rate, which was 
determined as 41.5%. There were no complete responses, 
but 27 patients had a partial response and 23 patients had 
stable disease. Median survival was 22 months. Similar to 
the other studies using this dosing schedule, toxicities were 
generally mild and managable. Twenty percent of patients 
developed grade 3 sensory neuropathy, and 51% had grade 1 
or 2 sensory neuropathy. Although grade 3 or 4 neutropenia 
was seen in 58% of patients, only 6 (9%) patients had febrile 
neutropenia or infections related to neutropenia.
Activity in other tumor types
Based on the activity of ixabepilone in a wide variety of tumor 
types in phase I studies, a number of phase II studies were 
designed to assess disease specifi c activity. In patients with 
nonsmall-cell lung cancer refractory to platinum drugs, ORR 
was 14.3% with 3-weekly dosing and 11.6% with daily dosing 
for 5 days, which is similar to other second-line treatments in 
this disease. The toxicity profi le was acceptable and included 
a 6% rate of grade 3 sensory neuropathy, and neutropenia was 
seen in 28% of patients receiving 3-weekly dosing and in 17% 
of patients receiving daily dosing (Vansteenkiste et al 2007). 
Acceptable response rates of 15%–48% with and without 
estramustine phosphate were seen in hormone-refractory 
prostate cancer. Grade 3 sensory neuropathy was seen in 
13%–17% of patients and rates of grade 3/4 neutropenia were 
17%–29% (Galsky et al 2005; Hussain et al 2005). Modest 
activity was also seen in patients with prostate cancer in the 
second-line setting who had progressed on fi rst-line docetaxel; 
however, half the patients developed grade 3/4 neutropenia 
(Rosenberg et al 2007). Final as well as preliminary phase 
II data with promising activity have also been presented in 
renal cell cancer (Fojo et al 2005), gynecologic cancers (Chen 
et al 2004), hepatobiliary cancer (Singh et al 2003), gastric 
cancer (Ajani et al 2006), pancreatic cancer (Whitehead et al 
2006), and nonHodgkin’s lymphoma (O’Connor et al 2005; 
Smith et al 2005).
Despite some suggestions of phase I activity, there has 
not been any meaningful effi cacy in phase II studies in 
melanoma, colorectal cancer, and sarcoma (Eng et al 2004; 
Pavlick et al 2004; Okuno et al 2005).
Phase III registration trial
Based on preclinical data showing synergism between 
ixabepilone and capecitabine (Lee 2006) and the results of 
the phase I/II study discussed above (Bunnell et al 2006), 
a phase III study was designed to examine the response to 
the combination compared with single-agent capecitabine 
(Thomas et al 2007). In this trial, 752 patients were ran-
domized to receive either capecitabine alone (2500 mg/m² 
orally on days 1–14 every 21 days) or capecitabine (2000 
mg/m²) in combination with ixabepilone (40 mg/m² every 
21 days). All patients had received prior anthracyclines and 
taxanes and almost half had received 2 prior therapies 
for metastatic disease. Dose reductions of ixabepilone or 
capecitabine were required in approximately half the patients 
in the combination arm, whereas 37% of patients in the 
single-agent capecitabine arm required a dose reduction. 
The primary endpoint was progression-free survival, which 
was signifi cantly improved in the combination therapy arm 
(5.8 months vs 4.2 months). The hazard ratio refl ected a 25% 
improvement in the estimated risk of disease progression 
favoring the combination. The objective response rate was 
35% with ixabepilone and capecitabine versus 14% with 
capecitabine alone (p  0.0001). In the combination arm 
41% of patients had stable disease compared with 46% in 
the single-agent capecitabine arm. As expected, incidence 
of sensory neuropathy was greater in the combination arm, 
although rates of severe hand-foot syndrome and diarrhea 
were similar in each arm. Grades 3/4 neutropenia were more 
Biologics: Targets & Therapy 2008:2(3)512
Puhalla and Brufsky
common in the combination arm, and any neutropenia was 
frequent in that arm (89%). In the single-agent capecitabine 
arm 43% of patients had any level of neutropenia.
Neoadjuvant trials
Ixabepilone has been used in the neoadjuvant setting in 
breast cancer in addition to the metastatic setting. A pre-
liminary report using a dose of 40 mg/m² every 21 days 
revealed a pathologic complete response rate (pCR) of 
21% of patients. Approximately 50% of patients were 
ER+. Grade 3 or 4 neutropenia was seen in 21% and 13% 
of patients, respectively. Grade 2 neuropathy was seen in 
11% of patients, whereas grade 3 neuropathy was seen in 
2% (Baselga et al 2005). Correlative studies revealed a 6 
gene predictive model that was able to predict benefi t to 
ixabepilone (Llmobart-Cussac et al 2005). Other preliminary 
data suggest a higher response rate in the triple negative 
(ER, PR, and HER2 negative) subgroup of breast cancer 
patients, with a pCR rate of 26% of the 42 triple negative 
patients and 15% in the 119 other patients given neoadjuvant 
ixabepilone (Roche et al 2006).
Safety
As evidenced in phase I and II trials, neuropathy and neutro-
penia are important potential toxicities. The neuropathy is 
primarily sensory and generally reversible in most patients 
with proper dose reductions and drug discontinuation (Perez 
et al 2007; Thomas et al 2007). Patients with diabetes have 
been shown to be at increased risk for the development of 
neuropathy and it is important to note that because patients 
with pre-existing neuropathy were excluded from clinical 
trials, their potential severity of neuropathy is unknown. 
Numerically it appears that daily dosing (Abraham et al 
2003; Low et al 2005; Denduluri et al 2007a; Denduluri 
et al 2007b) may be associated with less severe neuropathy 
(grade 3 neuropathy in 3%–4%) than in 3-weekly dosing 
(grade 3 in 13%–23%) (Perez et al 2007; Roche et al 2007; 
Thomas et al 2007). However, a study in nonsmall-lung 
cancer did not show any differences in neuropathy between 
3-weekly and daily dosing (Vansteenkiste et al 2007). The 
use of specifi c neurologic function tests to characterize the 
neuropathy associated with ixabepilone has been described 
(Lee et al 2006). The patients enrolled in a monotherapy 
trial of ixabepilone in breast cancer (Low et al 2005) had 
a number of neurologic function tests performed, includ-
ing Semmes-Weinstein monofi lament testing and modifi ed 
Romberg stance tests, which are used to assess diabetic 
neuropathy, and the Jebsen Test of Hand Function (JTH) 
and Grooved Pegboard Test (GPT), which are used to 
assess hand functions particularly in patients with stroke 
and rheumatoid arthritis. Twenty-three percent of patients 
developed grade 2 neuropathy (including decreased hand 
function, decreased sensory function, paresthesias, and motor 
weakness), 9 patients developing grade 2 neuropathy and 
2 patients developing grade 3 neuropathy. Three patients 
had refractory neuropathy that did not resolve to grade 1 up 
to 2 years after development. The results of JTH and GPT 
scores were found to be identifi able with onset of grade 12 
or higher peripheral neuropathy.
The most common overall adverse reactions seen in the 
monotherapy registration trial are summarized in Table 3 
(Perez et al 2007). When combined with capecitabine, tox-
icities commonly encountered with capecitabine such as 
palmar-plantar erythrodysesthesia and diarrhea were not 
signifi cantly increased. It is recommended that patients 
with known severe hypersensitivity to Cremophor® EL 
or derivatives, baseline ANC 1500 cells/mm3, platelets 
100,000 cells/mm3, or abnormal liver function (transami-
nases 2.5 × ULN or bilirubin 1 × ULN) do not receive 
ixabepilone.
Conclusions
Ixabepilone is an important addition to chemotherapeutic 
options for patients with MBC. The activity in patients who 
have failed previous taxanes makes this drug applicable for 
virtually all patients with MBC at some time in the course 
of their treatment. The high level of activity in the fi rst-line 
setting makes it an attractive option in that setting as well. 
The results of ongoing trials exploring the additional of vari-
ous biologic agents, such as trastuzumab and bevacizumab, 
are eagerly awaited (Cancer.gov 2008a, b, c). The strategy 
of combining chemotherapy with antiangiogenic agents is 
increasingly being used especially in the fi rst-line setting for 
Table 3 Nonhematologic adverse events seen in monotherapy 
registration trial
Nonhematologic  Total (%) Grade 3/4 (%)
adverse event (n = 126)
Peripheral sensory neuropathy 60 14
Fatigue/asthenia 56 13
Myalgia/arthralgia 49 8
Alopecia 48 0
Nausea 42 2
Stomatitis/mucositis 29 6
Vomiting 29 1
Diarrhea 22 1
Musculoskeletal pain 20 3
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MBC and the potential for improved activity exists with the 
other novel microtubule agents (Miller et al 2007). The tax-
anes in particular may potentiate the anti-angiogenic effects 
of these agents (Miller et al 2001; Sweeney et al 2001). 
A phase III trial conducted by the Cancer and Leukemia 
Group B (CALGB) and the North Central Cancer Treatment 
Group (NCCTG) is currently underway comparing the 
activity of various microtubule stabilizing agents with the 
vascular endothelial growth factor antibody bevacizumab. 
This trial is comparing weekly paclitaxel (90 mg/m²), nab-
paclitaxel (100 mg/m²), and ixabepilone (16 mg/m²) in 
combination with bevacizumab. This trial will also supply 
important information on the activity of these agents given 
in a “dose-dense” fashion, in which paclitaxel and arguably 
nab-paclitaxel have been found to have the greatest activity 
(Gradishar et al 2006; Seidman et al 2008; Sparano et al 
2008). There are a number of other agents that target the 
angiogenic as well as other important pathways with recent 
promising data (Rugo et al 2007) (Burstein et al 2008), and 
these agents may provide other rational combinations with 
ixabepilone. With the advent of new and possibly improved 
taxane agents, the question will be in what setting are these 
agents best used and whether they would replace traditional 
taxanes as the preference for fi rst-line therapy; or whether, 
perhaps because of activity in docetaxel- and paclitaxel-
resistant patients, their activity may be best reserved for 
patient with refractory disease. The role of ixabepilone 
will be best ascertained when it is directly compared with 
the other available taxanes in a variety of dosing schedules 
and lines of therapy. These questions will be best answered 
in the setting of a phase III randomized trial such as the 
CALGB/NCCTG one described above.
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